Multiple transduction pathways mediate thyrotropin receptor signaling in preosteoblast-like cells

Endocrinology

Volumn 157, Issue 5, 2016, Pages 2173-2181

  Boutin, Alisa ^a   Neumann, Susanne ^a   Gershengorn, Marvin C ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; INOSITOL PHOSPHATE; INTERLEUKIN 11; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OSTEOPONTIN; PERTUSSIS TOXIN; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C INHIBITOR; SMALL INTERFERING RNA; THYROTROPIN; THYROTROPIN RECEPTOR; ISOQUINOLINE DERIVATIVE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; U2OS CELL LINE; CELL LINE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE; COLFORSIN; HUMANS; INTERLEUKIN-11; ISOQUINOLINES; OSTEOBLASTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; SULFONAMIDES; THYROTROPIN; UP-REGULATION;

EID: 84969834740     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-2040     Document Type: Article

References (36)

1. Phan TC, Xu J, Zheng MH. Interaction between osteoblast and osteoclast: impact in bone disease. Histol Histopathol. 2004;19(4): 1325-1344.
2. Martin T, Gooi JH, Sims NA. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 2009; 19(1):73-88.
3. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473(2):201-209.
4. Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115(2):151-162.
5. Sampath TK, Simic P, Sendak R, et al. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res. 2007;22(6):849-859.
6. Sun L, Vukicevic S, Baliram R, et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci USA. 2008;105(11):4289-4294.
7. Baliram R, Sun L,CaoJ, et al. Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest. 2012; 122(10):3737-3741.
8. Baliram R, Latif R, Berkowitz J, et al. Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures. Proc Natl Acad Sci USA. 2011; 108(39):16277-16282.
9. Reddy PA, Harinarayan CV, Sachan A, Suresh V, Rajagopal G. Bone disease in thyrotoxicosis. Indian J Med Res. 2012;135(3):277-286.
10. Latif R, Morshed SA, ZaiDi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am. 2009; 38(2):319-341, viii.
11. Allen MD, Neumann S, Gershengorn MC. Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling. FASEB J. 2011;25(10):3687-3694.
12. Boutin A, Allen MD, Geras-Raaka E, Huang W, Neumann S, Gershengorn MC. Thyrotropin receptor stimulates internalization-independent persistent phosphoinositide signaling. Mol Pharmacol. 2011;80(2):240-246.
13. Boutin A, Eliseeva E, Gershengorn MC, Neumann S. Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation. FASEBJ. 2014;28(8):3446-3455.
14. Kleinau G, Neumann S, Grüters A, Krude H, Biebermann H. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev. 2013;34(5):691-724.
15. Bassett JH, van der Spek A, Logan JG, et al. Thyrostimulin regulates osteoblastic bone formation during early skeletal development. Endocrinology. 2015;156(9):3098-3113.
16. Pomerance M, Abdullah HB, Kamerji S, Correze C, Blondeau JP. Thyroid-stimulating hormone and cyclic AMP activate p38 mito-gen-activated protein kinase cascade. Involvement of protein kinase A, rac1, and reactive oxygen species. J Biol Chem. 2000;275(51): 40539-40546.
17. Jing Q, Xin SM, Cheng ZJ, et al. Activation of p38 mitogen-activated protein kinase by oxiDized LDL in vascular smooth muscle cells: mediation via pertussis toxin-sensitive G proteins and association with oxiDized LDL-induced cytotoxicity. Circ Res. 1999; 84(7):831-839.
18. Wolf M, Jäger A, Abuduwali N, Götz W, Lossdörfer S. Continuous PTH modulates alkaline phosphatase activity in human PDL cells via protein kinase C dependent pathways in vitro. Ann Anat. 2013; 195(5):455-460.
19. Naor Z, Benard O, Seger R. Activation of MAPK cascades by Gprotein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab. 2000;11(3):91-99.
20. May LT, Hill SJ. ERK phosphorylation: spatial and temporal regulation by G protein-coupled receptors. Int J Biochem Cell Biol. 2008;40(10):2013-2017.
21. Neubig RR, Enna SJ. Pharmacology of G Protein Coupled Receptors. San Diego, CA: Academic Press; 2011.
22. Galandrin S, Bouvier M. Distinct signaling profiles of 1 and 2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006;70(5):1575-1584.
23. Sims NA, Jenkins BJ, Nakamura A, et al. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res. 2005;20(7):1093-1102.
24. Roger PP, Christophe D, Dumont JE, Pirson I. The dog thyroid primary culture system: a model of the regulation of function, growth and differentiation expression by cAMP and other welldefined signaling cascades. Eur J Endocrinol. 1997;137(6):579-598.
25. Tramontano D, Moses AC, Veneziani BM, Ingbar SH. Adenosine 3-,5-monophosphate mediates both the mitogenic effect of thyrotropin and its ability to amplify the response to insulin-like growth factor I in FRTL5 cells. Endocrinology. 1988;122(1):127-132.
26. Nakabayashi K, Matsumi H, Bhalla A, et al. Thyrostimulin, a heterodimer of two new human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor. J Clin Invest. 109(11):1445-1452.
27. Sun SC, Hsu PJ,WuFJ, Li SH, Lu CH, Luo CW. Thyrostimulin, but not thyroid-stimulating hormone (TSH), acts as a paracrine regulator to activate theTSHreceptor in mammalian ovary. J BiolChem. 2010;285(6):3758-3765.
28. Sinha P, Aarnisalo P, Chubb R, et al. Loss of Gs in the postnatal skeleton leads to low bone mass and a blunted response to anabolic parathyroid hormone therapy. J Biol Chem. 2016;291(4):1631-1642.
29. Gesty-Palmer D, Chen M, Reiter E, et al. Distinct arrestin-and G protein-dependent pathways for parathyroid hormone receptorstimulated ERK1/2 activation. J Biol Chem. 2006;281(16):10856-10864.
30. Gesty-Palmer D, Flannery P, Yuan L, et al. A arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med. 2009;1(1):1ra1.
31. Bisello A, Chorev M, Rosenblatt M, Monticelli L, Mierke DF, Ferrari SL. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem. 2002;277(41):38524-38530.
32. Ferrari SL, Pierroz DD, Glatt V, et al. Bone response to intermittent parathyroid hormone is altered in mice null for Arrestin2. Endocrinology. 2005;146(4):1854-1862.
33. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid. 2003;13(6):585-593.
34. Brassill MJ, Williams GR. Advances in our understanDing of hyperthyroidism-associated bone loss. Eur Endocrinol. 2009;4:103-106.
35. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest. 58(3):529-534.
36. Sivertsen B, Holliday N, Madsen AN, Holst B. Functionally biased signalling properties of 7TM receptors-opportunities for drug development for the ghrelin receptor. Br J Pharmacol. 2013;170(7): 1349-1362.